A new co-operative group: the European Myeloma Network Trialist Group
DOI: 10.1080/10428190903191874
Publication date: October 2009
Publications
Autologous Haematopoietic Stem-Cell Transplantation Versus Bortezomib-Melphalan-Prednisone, With or Without Bortezomib-Lenalidomide-Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (EMN02/HO95): A Multicentre, Randomised, Open-Label, Phase 3 Study
Main author: Cavo
DOI: 10.1016/S2352-3026(20)30099-5
Publication date: June 2020
Connected Trials:
EMN02
Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
Main author: Bringhen
DOI: 10.3324/haematol.2018.191288
Publication date: September 2018
Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma: A Consensus Statement From The European Myeloma Network
Main author: Moreau
DOI: 10.3324/haematol.2019.224204
Publication date: December 2019
Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.
Main author: Cook
DOI: 10.1038/s41375-020-0918-6
Publication date: June 2020
European Myeloma Network guidelines for the management of multiple myeloma-related complications
Main author: Terpos
DOI: 10.3324/haematol.2014.117176
Publication date: January 2015
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
Main author: Gavriatopoulou
DOI: 10.1038/s41375-018-0209-7
Publication date: September 2018
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Main author: Engelhardt
DOI: 10.3324/haematol.2013.099358
Publication date: January 2014
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Main author: Caers
DOI: 10.3324/haematol.2018.189159
Publication date: November 2018
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
Main author: Engelhardt
DOI: 10.3109/10428194.2010.516378
Publication date: January 2010
European myeloma network: the value of collaborative research
Main author: Sonneveld
DOI: 10.1159/000087039
Publication date: January 2005
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
Main author: Gay
DOI: 10.3324/haematol.2017.174573
Publication date: February 2018
Insights on Multiple Myeloma Treatment Strategies
Main author: Mateos
DOI: 10.1097/HS9.0000000000000163
Publication date: December 2018
Lenalidomide Maintenance With or Without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis
Main author: Bonello
DOI: 10.3390/cancers11111735
Publication date: November 2019
Connected Trials:
EMN01
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.
Main author: Gay
DOI: 10.1001/jamaoncol.2018.2961
Publication date: October 2018
Management of Patients With Multiple Myeloma in the Era of COVID-19 Pandemic: A Consensus Paper From the European Myeloma Network (EMN)
Main author: Terpos
DOI: 10.1038/s41375-020-0876-z
Publication date: May 2020
Minimal Residual Disease by Flow Cytometry and Allelic-Specific Oligonucleotide Real-Time Quantitative Polymerase Chain Reaction in Patients With Myeloma Receiving Lenalidomide Maintenance: A Pooled Analysis
Main author: Gambella
DOI: 10.1002/cncr.31854
Publication date: March 2019
Connected Trials:
EMN02
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
Main author: Bringhen
DOI: 10.1038/s41375-018-0024-1
Publication date: January 2018
Connected Trials:
EMN07
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Main author: Dimopoulos
DOI: 10.1038/leu.2011.3.
Publication date: January 2011
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
Main author: Larocca
DOI: 10.1038/s41375-018-0142-9
Publication date: January 2018
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
Main author: Palumbo
DOI: 10.1182/blood-2011-06-358812
Publication date: January 2011
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
Main author: Sonneveld
DOI: 10.1182/blood-2014-05-576256.
Publication date: January 2015
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
Main author: Ludwig
DOI: 10.1038/leu.2017.353
Publication date: January 2017
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Main author: Ludwig
DOI: 10.1038/s41375-018-0040-1
Publication date: January 2018
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
Main author: Bringhen
DOI: 10.1111/joim.12882
Publication date: February 2019
- 1
- 2